NASDAQ:RNA Avidity Biosciences (RNA) Stock Price, News & Analysis $48.14 +3.42 (+7.65%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$45.09▼$48.2950-Day Range$26.04▼$48.1452-Week Range$4.82▼$48.29Volume1.00 million shsAverage Volume1.55 million shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/APrice Target$44.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Avidity Biosciences alerts: Email Address Avidity Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.0% Downside$44.29 Price TargetShort InterestBearish13.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 11 Articles This WeekInsider TradingSelling Shares$16.99 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.15) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.12 out of 5 starsMedical Sector926th out of 936 stocksPharmaceutical Preparations Industry432nd out of 436 stocks 1.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Avidity Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.50% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 19.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 1.9 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,993,310.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Avidity Biosciences is held by insiders.Read more about Avidity Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.15) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 7.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avidity Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Avidity Biosciences Stock (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNA Stock News HeadlinesJuly 25 at 5:06 AM | insidertrades.comArthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJuly 12, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sarah Boyce Sells 28,000 SharesJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 27 at 12:07 AM | markets.businessinsider.comCantor Fitzgerald Keeps Their Buy Rating on Avidity Biosciences (RNA)July 26 at 5:26 AM | msn.comINTEGRA Biosciences and Parse Biosciences offer affordable, automated single cell RNA sequencingJuly 24 at 6:41 AM | investorplace.com3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)July 23, 2024 | fool.com3 Russell 2000 Growth Stocks That Could Be Worth the RiskJuly 22, 2024 | prnewswire.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.June 21, 2024 | prnewswire.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 20, 2024 | prnewswire.comAvidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD DayJune 17, 2024 | prnewswire.comAvidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJune 14, 2024 | seekingalpha.comAvidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' UpgradeJune 14, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferenceJune 13, 2024 | prnewswire.comAvidity Biosciences, Inc. Announces Pricing of Public Offering of Common StockJune 12, 2024 | prnewswire.comAvidity Biosciences, Inc. Announces Proposed Public Offering of Common StockJune 12, 2024 | investors.comThe 'Impressive' Results That Sent Top 1% Avidity Biosciences To A RecordJune 12, 2024 | benzinga.comCasey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On WednesdaySee More Headlines Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/27/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$44.29 High Stock Price Target$60.00 Low Stock Price Target$30.00 Potential Upside/Downside-8.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-212,220,000.00 Net Margins-2,103.78% Pretax Margin-2,103.78% Return on Equity-37.98% Return on Assets-33.09% Debt Debt-to-Equity RatioN/A Current Ratio12.47 Quick Ratio12.47 Sales & Book Value Annual Sales$9.56 million Price / Sales481.60 Cash FlowN/A Price / Cash FlowN/A Book Value$6.76 per share Price / Book7.12Miscellaneous Outstanding Shares95,640,000Free Float92,118,000Market Cap$4.60 billion OptionableOptionable Beta0.90 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Troy Edward Wilson J.D. (Age 55)Ph.D., Co-Founder & Independent Chairman Comp: $70kMs. Sarah Boyce (Age 52)President, CEO & Director Comp: $998.88kMr. Michael F. MacLean (Age 58)Chief Financial & Chief Business Officer Comp: $674.74kDr. W. Michael F. Flanagan Ph.D. (Age 61)Chief Scientific & Technical Officer Comp: $675.22kMs. Teresa McCarthy (Age 60)Chief Human Resources Officer Comp: $628.79kDr. Arthur A. Levin Ph.D. (Age 70)Distinguished Scientist, Strategic Leader & Director Comp: $304.69kMr. Eric B. Mosbrooker (Age 57)Chief Strategy Officer Comp: $45kProf. Mark E. Davis Ph.D.Scientific Founder, Member of Scientific Advisory Board and Member of Board of ManagersDr. Frank P. McCormick Ph.D. (Age 74)Scientific Founder & Member of Scientific Advisory Board Mr. Geoffrey M. Grande C.F.A.VP of Investor Relation & Corporate CommunicationMore ExecutivesKey CompetitorsCytokineticsNASDAQ:CYTKPTC TherapeuticsNASDAQ:PTCTConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 115,676 shares on 7/26/2024Ownership: 0.381%EFG Asset Management North America Corp.Bought 29,992 shares on 7/26/2024Ownership: 0.031%Moss Adams Wealth Advisors LLCBought 38,213 shares on 7/23/2024Ownership: 0.040%China Universal Asset Management Co. Ltd.Sold 4,064 shares on 7/20/2024Ownership: 0.012%Nisa Investment Advisors LLCBought 1,076 shares on 7/20/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions RNA Stock Analysis - Frequently Asked Questions How have RNA shares performed this year? Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA shares have increased by 431.9% and is now trading at $48.14. View the best growth stocks for 2024 here. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) posted its quarterly earnings results on Wednesday, May, 15th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.02. The biotechnology company earned $3.54 million during the quarter, compared to the consensus estimate of $7.09 million. Avidity Biosciences had a negative net margin of 2,103.78% and a negative trailing twelve-month return on equity of 37.98%. When did Avidity Biosciences IPO? Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO. Who are Avidity Biosciences' major shareholders? Avidity Biosciences' top institutional investors include Bank of New York Mellon Corp (0.38%), Raymond James & Associates (0.16%), SG Americas Securities LLC (0.10%) and Hennion & Walsh Asset Management Inc. (0.08%). Insiders that own company stock include Sarah Boyce, Michael F Maclean, W Michael Flanagan, Arthur A Levin and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX) and iBio (IBIO). This page (NASDAQ:RNA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts